Pfizer Chief Executive Officer Albert Bourla reiterated on Wednesday his optimistic view that the company’s experimental coronavirus vaccine is a strong competitor and could cross key barriers on its way to the public this fall.
I think by the end of October we have a very good chance to find out if the vaccine works, Borla said, moderated during a virtual virtual discussion.
Bourla stressed that the vaccine, which is being developed in conjunction with the German biotech company BioNTech, would have to be validated through Phase III clinical studies to establish its safety and efficacy. However, Pfizer believes through its model that there is a more than 60% chance that companies will know by the end of October if it really works or not.
In the event of an epidemic, people will inevitably be allowed to live their lives with COVID, and as Borla said, it is important to measure the infection gap between study participants and those receiving the experimental vaccine.
The theme was purpose-driven business, and Bourla spoke about that as well.
Although Pfizer says it has no plans to benefit patients during the global outbreak and will base its prices on optimal prices, Borla still feels it will help the company in the long run: “Bringing the vaccine a Will be a big step; ” I am not a saint, but we will earn money by making good science. “
